Altana Pharma Ag

Byk Gulden Lomberg Chemische Fabrik Gmbh

Other

Thomas Martin

Wolf-Rudiger Ulrich

Robert Huber

Luis Moroder

Josef Stadlwieser

Wolfram Bode

Wolf-R&uuml;diger Ulrich

Thomas B&auml;r

Ulrich Thibaut

Rolf Beume

Christian Sommerhoff

Daniela Bundschuh

Norbert Schaschke

Andreas Bergner

Pedro Jose Barbosa Pereira

Andreas Dominik

Karl-Josef Goebel

Wolf-Rüdiger Ulrich

Wolf-Ruediger Ulrich

The compounds of formula I in which R1, R2, R3 and A have the meanings as given in the description are novel effective INOS inhibitors.

Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors

Compounds of the formula I, in which M, A1, A2, K1 and K2 have the meanings given in the description are novel effective tryptase inhibitors.

Tryptase inhibitors

Compounds of the formula (I), in which M is a central building block selected from the group below in which A1, A2, K1 and K2 are as defined in the description, are novel effective tryptase inhibitors.

Compounds of the formula (I), in which M, A1, A2, K1 and K2 have the meanings indicated in the description are novel active tryptase inhibitors.

The compounds of formula Iin which M, B1, B2, R1, R2, R6, R7, K1 and K2 have the meanings as indicated in the description are novel active tryptase inhibitors.

Compounds of formula (I)in which M, B1, B2, B3, B4, B5, B6, A1, A2, A3, A4, A5, A6, K1 and K2 have the meanings as indicated in the description, are novel effective tryptase inhibitors.

Compounds of formula (I), in which M, A1, A2, K1 and K2 have the meanings as indicated in the description are novel active tryptase inhibitors.

The invention relates to novel inhibitors of human tryptase which are used in the pharmaceutical industry for the production of medicaments.

Growing community of inventors

Constance, Germany

Thomas Martin